---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-087372"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T15:15:23.886416+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports $17.3M Q4 loss; IND cleared for ALK inhibitor NVL-655

## Summary
- Q4 2021 net loss $17.3M; full-year net loss $46.3M, vs $14.6M in 2020.
- Cash, equivalents, marketable securities $288.1M as of Dec 31, 2021; runway into 2024.
- FDA cleared IND for NVL-655 (ALK-selective); ALKOVE-1 Phase 1/2 to start Q2 2022.
- ARROS-1 trial of NVL-520 (ROS1) actively enrolling Phase 1 patients.
- Discovery pipeline targeting ALK resistance and HER2 exon 20; 2 candidate nominations expected in 2022.

## SEC filing metadata
- accession: 0001193125-22-087372
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000119312522087372/0001193125-22-087372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000119312522087372/d307870d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-087372
- JSON: https://secwatch.observer/filing/0001193125-22-087372.json
- Plain text: https://secwatch.observer/filing/0001193125-22-087372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.